In this new article, our team at the University of Galway reviewed and analysed current research on the use of MSCs and MSC-EVs in treating corneal diseases.
restorevision@catalyze-group.com
New article: Are inactive ingredients in eye drops safe? A closer look at excipients safety, function an regulation.
Restore Vision has conducted the first comprehensive review of FDA-approved excipients in ophthalmic medications, examining their roles, safety, and the regulatory pathways required for approval for human use.
Restore Vision’s first review meeting
On January, 30. The RESTORE VISION team held its first review meeting to assess project progress and discuss plans for the upcoming year.
Partecipa al nostro studio presso l’Ospedale San Raffaele di Milano!
Aiutaci a far progredire la ricerca sulle malattie oculari rare!
Participate in our study in Milan, Italy!
Join our study in Milan, Italy and help us advance research on rare eye conditions!
Restore Vision at EVER 2024
Read more about Restore Vision Special Interest Session at EVER 2024 Congress
Restore Vision team participates in DOG 2024 Congress
Last October 10, the Restore Vision team participated in the Deutsche Ophthalmologische Gesellschaft – DOG 2024.
Restore Vision 2nd consortium meeting
One year after the project kicked-off, our team met again in-person in Stockholm!
Restore Vision partners jointly host the 7th European Anirida Conference
Restore Vision partners participated in 7th European Aniridia Conference.
Antisense eye drops only or combined with fine needle diathermy could be used to regress corneal neovascularization in mice – study by UKK
At the recent ARVO meeting, Wei Zhang presented the latest findings from the University of Cologne on a new treatment to regress corneal neovascularization in mice